**WEB REQUIREMENTS**

|  |  |  |  |
| --- | --- | --- | --- |
| **Project Name (internal)** | ASH PDS | **Project Code** | PI4VDS112 |
| **Virtual Project Manager** | Meg Quick | **Clinical Program Manager** | Chelsey/Briana |
| **Compliance** | Briana Devaser | **Editor** | Heather/Christi |

**Launch Date/Internal Launch Date:**

**Project Type**

Video

Downloadable Slides

Other:

**Email Blast Included?**

Yes

No

Subject Line:

**Number of E-Blasts**

Only One

Two

Three  
Other Amount:

Dates to Blast or Special Requests:

**Cross Promotion**

Yes

No

If Yes, List Activities:

Oncology Guru, ASH DCUs

**Target Audience**

US  
EX-US  
Global (Both EX-US & US)  
Other or Special:

Additional Emails (Supporters?):

**Slides**

Slides Included

Yes

No

**CME?**

Yes- Point of Care CME

No

Webcast/PDS URL:

**www.primeoncology.org/2014\_sanfrancisco\_pds**

**Additional Components**

Cases with Voting

Polls

Video Segmentation

Table of Contents

Other:

**Mobile App Title: ASH Presentations**

**Listing Page**

**[Insert small PDS Graphic to the left]**

**[TITLE]**

prIME Downloadable Slides From the 2014 Annual Hematology Meeting in San Francisco

**[DATE** | **LOCATION]**

December 2014 | San Francisco, California

**[Insert PDS Graphic header]**

**[Insert Text below]**

prIME Downloadable Slides From the 2014 Oncology Annual Meeting in Chicago

**Activity Features**

**[Insert icon]** Downloadable Slides

**[CME icon]** CME-Certified

**Activity Overview**

prIME Downloadable Slides from the 2014 Annual Hematology Meeting in San Francisco

**Provider**

This activity is provided by prIME Oncology.

**Support**

This educational activity is supported by grants from Boehringer Ingelheim and Novartis Oncology.

**[Insert List of Disease Type Tabs]**

* All
* AML
* MM FL
* MM RR

**[Tab- AML]**

Acute Myeloid Leukemia

Featured Abstracts:

**Abstract #LBA-6:** Improved Survival in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated With Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)

**Abstract #10:** Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (>30% Bone Marrow Blasts) With Myelodysplasia-Related Changes: A Subgroup Analysis of the AZA-AML-001 Trial

**Abstract #376:** Final Analysis of the ALFA 0701 Study

**Abstract #979:** The Novel Plk Inhibitor Volasertib Overcomes Cytarabine Resistance in Acute Myeloid Leukemia

**View**

**[Tab-MM FL ]**

Multiple Myeloma: Front-Line

Featured Abstracts:

**Abstract #33:** Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy With Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

**Abstract #82:** Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) With Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

**Abstract #175:** Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCd) in Newly Diagnosed Multiple Myeloma Patients: A Phase I- II Study

**Abstract #198:** Impact of Autologous Transplantation vs. Chemotherapy Plus Lenalidomide in Newly Diagnosed Myeloma According to Patient Prognosis: Results of a Pooled Analysis of 2 Phase III Trials

**View**

**[Tab- MMRR]**

Multiple Myeloma: Relapsed/Refractory

Featured Abstracts:

**Abstract #31:** Ibrutinib, Single Agent or in Combination With Dexamethasone, in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results

**Abstract #79:** Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) With Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study

**Abstract #80:** Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

**Abstract #4742:** Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study

**View**

**CME Page**

**Release Date**   
December XX, 2014   
  
**Expiration Date**   
December XX, 2015

**Learning Objectives**After successful completion of this educational activity, participants should be able to:

* Evaluate recent findings from studies investigating biomarkers and molecular features of hematologic malignancies and disorders
* Apply emerging data from clinical trials evaluating novel agents and treatment approaches for hematologic malignancies and disorders
* Identify appropriate clinical trials and refer eligible patients with hematologic malignancies and disorders for enrollment to expand their treatment options

**Provider**

This activity is provided by prIME Oncology.

**Support [USE SAME AS ABOVE]**

**Target Audience**   
This educational activity is specifically designed for practicing hematologists, medical oncologists, and other healthcare professionals interested in and/or involved in the treatment of patients with cancer.

**CONTINUING EDUCATION**

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

[Insert ACCME logo]

prIME Oncology designates this internet point of care (PoC) activity for a maximum of 1.5 *AMA PRA Category 1 Credit*s™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

prIME Oncology designates each Internet PoC cycle for 0.5 *AMA PRA Category 1 Credits™.*

Each module may award the following:

AML: 0.5

MM FL: 0.5

MM RR: 0.5

**Method of Participation**

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must complete the activity evaluation and successfully find an answer to their clinical question and document it in the online point of care questionnaire. Your participation in this CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the [Terms of Use](http://www.primeoncology.org/footer-e-pages/terms_of_use.aspx).

A link to the questionnaire is available on the video player page.

In order to receive credit, participants must successfully find an answer to their clinical question and document it in the online point of care questionnaire.

**Disclosure of Relevant Financial Relationships**

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The employees of prIME Oncology have disclosed:

• Chelsey Goins, PhD (clinical content planner/reviewer) – no relevant financial relationships

• Trudy Stoddert, ELS (editorial content planner/reviewer) – no relevant financial relationships

**Disclosure Regarding Unlabeled Use**

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

**Disclaimer**

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities